Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

• Published in: Diabetes therapy Vol. 12; no. 3; pp. 843 - 861
• Main Authors: Chehrehgosha, Haleh, Sohrabi, Masoud Reza, Ismail-Beigi, Faramarz, Malek, Mojtaba, Reza Babaei, Mohammad, Zamani, Farhad, Ajdarkosh, Hossein, Khoonsari, Mahmood, Fallah, Afshin Eshghi, Khamseh, Mohammad E.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.03.2021; Springer; Springer Nature B.V
• Subjects: Antidiabetics; Cardiology; Diabetes; Double-blind studies; Drug therapy; Endocrinology; Fatty liver; Hepatitis; Insulin; Internal Medicine; Liver diseases; Medicine; Medicine & Public Health; Original Research; Patient outcomes; Type 2 diabetes; Iran; Empagliflozin; Nonalcoholic steato-hepatitis (NASH); Pioglitazone; Fibroscan; Non-alcoholic fatty liver disease (NAFLD); Liver fibrosis; Body composition; Steatosis

Introduction To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). Methods In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to recei...